Mechanism of Action
Recombinant GLP-2 analogue; activates GLP-2 receptors on intestinal subepithelial myofibroblasts and enteroendocrine cells to promote villus hypertrophy, crypt depth, and mucosal surface area in remaining small bowel, improving nutrient absorption in short bowel syndrome.
Simplified Summary
GLP-2 (glucagon-like peptide 2) is co-encoded with GLP-1 in the proglucagon gene but has entirely different biological effects: where GLP-1 regulates appetite and insulin secretion, GLP-2 promotes intestinal epithelial growth, increases villus height, deepens crypts, and enhances nutrient absorption capacity. Teduglutide is a recombinant GLP-2 analogue with a proline substitution that extends its half-life from approximately 7 minutes (native GLP-2) to approximately 2 hours.
Short bowel syndrome (SBS) with intestinal failure results from surgical resection of significant lengths of small bowel (trauma, Crohn's disease, mesenteric ischaemia, necrotising enterocolitis) leaving insufficient absorptive surface for adequate nutrition absorption. Patients require parenteral nutrition (IV feeding) to survive. Teduglutide promotes the remaining bowel to hypertrophy and absorb more efficiently, enabling reduction or elimination of parenteral nutrition dependence.
Clinical trials demonstrated that teduglutide treatment reduced parenteral nutrition requirements by approximately 4.4 hours per week versus placebo in SBS-IF patients, with approximately 63% of teduglutide patients achieving clinically meaningful PN reduction. This makes it one of the very few pharmaceutical agents that can modify the course of intestinal failure rather than merely managing its consequences.
Key Findings Reported in Clinical Research
- Parenteral nutrition reduction: Phase 3 STEPS trial data demonstrated significantly greater reductions in parenteral nutrition volume and duration in teduglutide versus placebo groups in SBS-IF patients.
- Intestinal morphology: Endoscopic and biopsy studies have documented villus height increases and crypt depth increases in small bowel tissue biopsies from teduglutide-treated patients, confirming the expected intestinal trophic effect.
- Absorptive function improvement: Citrulline (a validated biomarker of functional enterocyte mass) increases have been documented in clinical trials, providing objective evidence of improved absorptive capacity.
- Colonoscopy surveillance requirement: Clinical data identified intestinal polyp growth as a safety concern requiring systematic colonoscopy surveillance, establishing a mandatory monitoring protocol for long-term teduglutide use.
- GLP-2 pathway biology: Teduglutide has contributed to understanding of GLP-2 receptor-mediated intestinal growth, crypt-villus axis biology, and the factors regulating small bowel adaptive response.
Introduction
The enteroendocrine system of the small bowel includes L-cells that secrete both GLP-1 and GLP-2 in response to nutrients. GLP-2's intestinotrophic effects were characterised in the 1990s, establishing the receptor (GLP-2R) and the downstream signalling responsible for maintaining small bowel mucosal integrity and growth. Teduglutide's development translated this biology into a therapeutic approach for intestinal failure.
The distinction from GLP-1 compounds is fundamental: teduglutide does not cause weight loss, appetite suppression, or insulin modulation. Its entire clinical utility derives from intestinal epithelial proliferation and enhanced nutrient absorption. The compounds share a GLP prefix but act on entirely different receptors with entirely different physiological effects.
Short bowel syndrome with intestinal failure represents a rare but life-threatening condition affecting approximately 3 per million population. Teduglutide's approval represents one of very few disease-modifying treatments for this condition.
Research Applications
- Intestinal biology research: GLP-2R-mediated crypt-villus axis regulation, villus hypertrophy mechanisms, and the biology of intestinal adaptation to bowel resection.
- Short bowel syndrome models: Preclinical and clinical studies examining adaptive intestinal response, parenteral nutrition-weaning protocols, and the biology of intestinal failure and recovery.
- GLP peptide comparative pharmacology: Research examining the distinct receptor targeting and physiological effects of GLP-1 versus GLP-2 pathway activation as a model for understanding proglucagon-derived peptide biology.
What to Expect
Peptide is accumulating in target tissue. Baseline measurements recommended before changes become apparent.
Downstream effects begin to compound. Key biomarkers worth re-assessing at this stage.
End-of-cycle data collection recommended. Human trial literature provides a benchmark for comparison.
Frequently Asked Questions
For research use only. Capital Products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.